menu
    • menu

    Company profile for Aligos Therapeutics

    NEW Drugs in Dev: 8
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aligos Therapeutics, Inc. is a privately held biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 as well as leveraging its expertise in liver diseases to create targeted therapeutics for NASH. Aligos’ strategy is to h...
    Aligos Therapeutics, Inc. is a privately held biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 as well as leveraging its expertise in liver diseases to create targeted therapeutics for NASH. Aligos’ strategy is to harness the deep expertise and decades of drug development experience of its workforce in liver disease, particularly viral hepatitis, to rapidly advance a portfolio of best-in-class drug candidates.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aligos TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1 Corporate Dr., 2nd Floor South San Francisco, CA 94080
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aligos.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/aligos-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Aligos7

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aligos Pharma Appoints James Hassard As EVP, CCO
    Aligos Pharma Appoints James Hassard As EVP, CCO

    13 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/13/3217728/0/en/Aligos-Therapeutics-Strengthens-Senior-Leadership-Team-with-the-Appointment-of-James-Hassard-as-Executive-Vice-President-Chief-Commercial-Officer.html

    GLOBENEWSWIRE
    13 Jan 2026
    Share Share
    Aligos Therapeutics Issues Inducement Grants Per Nasdaq LR
    Aligos Therapeutics Issues Inducement Grants Per Nasdaq LR

    12 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/12/3204598/0/en/Aligos-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    12 Dec 2025
    Share Share
    Aligos Therapeutics Presents Positive Data At HEP-DART 2025
    Aligos Therapeutics Presents Positive Data At HEP-DART 2025

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203835/0/en/Aligos-Therapeutics-Presents-Positive-Data-at-HEP-DART-2025.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Aligos Therapeutics Issues Inducement Grants Per Nasdaq LR
    Aligos Therapeutics Issues Inducement Grants Per Nasdaq LR

    14 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/14/3188250/0/en/Aligos-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    14 Nov 2025
    Share Share
    Aligos Therapeutics Presents Positive Data at Liver Meeting
    Aligos Therapeutics Presents Positive Data at Liver Meeting

    10 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/10/3184522/0/en/Aligos-Therapeutics-Presents-Positive-Data-at-The-Liver-Meeting-2025.html

    GLOBENEWSWIRE
    10 Nov 2025
    Share Share
    Aligos Therapeutics Updates Business Progress & Q3 2025
    Aligos Therapeutics Updates Business Progress & Q3 2025

    06 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/06/3182594/0/en/Aligos-Therapeutics-Reports-Recent-Business-Progress-and-Third-Quarter-2025-Financial-Results.html

    GLOBENEWSWIRE
    06 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search